Dashboard
Manage Tickers

GILD GILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 123.13 $ 0.30 (0.24 %)    

Monday, 20-Oct-2025 17:14:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 123.11
$ 122.59
$ 122.00 x 10
$ 123.75 x 25
$ 122.20 - $ 123.99
$ 83.12 - $ 124.11
8,149,673
na
152.76B
$ 0.48
$ 24.20
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-23-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-25-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-06-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 02-27-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-24-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-sunday-gilead-sciences-phase-3-ascent-03-study-shows-trodelvy-cut-risk-of-disease-progression-or-death-by-38-versus-chemotherapy-in-first-line-metastatic-triple-negative-breast-cancer
Reported Sunday, Gilead Sciences' Phase 3 ...
10/20/2025 07:47:49

– Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine –– Wi...

reported-sunday-gilead-showcases-34-presentations-including-six-oral-sessions-across-hiv-respiratory-viruses-viral-hepatitis-pandemic-pathogens-at-idweek
Reported Sunday, Gilead Showcases 34 Prese...
10/20/2025 07:29:52

– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option A...

uk-health-agency-recommends-gsk-backed-viiv-healthcares-apretude-as-injectable-hiv-treatment
UK Health Agency Recommends GSK-Backed Vii...
10/17/2025 16:43:32

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...

mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials
Merck's New HIV Treatment Works As Well As...
10/15/2025 16:23:05

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

gilead-presents-latest-clinical-data-on-lenacapavir-biktarvy-and-novel-long-acting-hiv-combinations-at-eacs-2025
Gilead Presents Latest Clinical Data On Le...
10/15/2025 07:56:04

 New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Re...

gilead-sciencesarcus-biosciences-investigational-cancer-drug-shows-overall-survival-of-around-27-months
Gilead Sciences/Arcus Biosciences' Investi...
10/13/2025 14:33:57

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combinatio...

gilead-coinbase-rocket-lab-and-a-tech-stock-on-cnbcs-final-trades
Gilead, Coinbase, Rocket Lab And A Tech St...
10/13/2025 12:32:20

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

Core News & Articles
CNBC Halftime Report Final Trades: Gilead...
10/10/2025 17:01:36

breaking-down-gilead-sciences-6-analysts-share-their-views
Breaking Down Gilead Sciences: 6 Analysts ...
10/08/2025 22:01:01

citigroup-maintains-buy-on-gilead-sciences-raises-price-target-to-135
Citigroup Maintains Buy on Gilead Sciences...
10/08/2025 18:33:25

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $125 to ...

heres-how-much-you-would-have-made-owning-gilead-sciences-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
10/07/2025 23:45:27

gilead-says-for-q3-co-currently-expects-1704m-in-acquired-iprd-expenses-co-sees-acquired-iprd-expenses-to-represent-charge-of-about-011-to-both-gaap-and-non-gaap-eps
Gilead Says For Q3, Co Currently Expects $...
10/07/2025 20:27:23

- SEC Filing

gilead-reaches-settlement-to-block-biktarvy-generics-until-2036
Gilead Reaches Settlement To Block Biktarv...
10/06/2025 16:24:28

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until A...

gilead-settles-patent-disputes-to-block-generic-biktarvy-launch-in-us-until-april-2036
Gilead Settles Patent Disputes To Block Ge...
10/06/2025 12:24:50

On October 6, 2025, Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced that it has entered into settle...

gilead-sciences-entered-into-settlement-agreement-to-resolve-patent-litigation-with-lupin-cipla-and-laurus-labs-for-biktarvy
Gilead Sciences Entered Into Settlement Ag...
10/06/2025 12:22:32

https://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm

is-gilead-sciences-inc-gaining-or-losing-market-support
Is Gilead Sciences Inc Gaining or Losing M...
10/02/2025 20:00:53

these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap
These 3 Pharma Stocks Are Rallying – And S...
10/02/2025 19:43:25

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

market-whales-and-their-recent-bets-on-gild-options
Market Whales and Their Recent Bets on GIL...
10/02/2025 18:01:29

gilead-pledges-65m-to-boost-stem-education-and-close-americas-skills-gap
Gilead Pledges $6.5M To Boost STEM Educati...
09/29/2025 09:53:47

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward stren...

if-you-invested-100-in-gilead-sciences-stock-20-years-ago-you-would-have-this-much-today
If You Invested $100 In Gilead Sciences St...
09/23/2025 22:45:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION